Literature DB >> 1977764

Comparison of Western immunoblot antigens and interpretive criteria for detection of antibody to human T-lymphotropic virus types I and II.

D Gallo1, J L Diggs, C V Hanson.   

Abstract

Twenty human T-lymphotropic virus type I (HTLV-I) antibody-positive sera from Japan, Hawaii, and the Marshall Islands and 15 HTLV type II (HTLV-II) antibody-positive sera from intravenous drug users in the United States were tested by immunoblotting with two recombinant HTLV-I proteins and three commercial kits to determine whether there were any differences in reactions between HTLV-I- and HTLV-II-positive sera by the Western immunoblot method and, also, to evaluate the ability of these reagents to detect HTLV-I- and HTLV-II-seropositive individuals by using the recommended Western blot interpretation. These sera were first extensively characterized by immunofluorescence, enzyme immunoassay, radioimmunoprecipitation assay, and Western blot using HTLV-I and HTLV-II viral lysates and an envelope (env) recombinant protein. Although both HTLV-I- and HTLV-II antibody-positive sera reacted with the env protein gp68, reactions with the gp46 env antigens appeared to be specific for HTLV-I. It was found that the use of either p19 or p24 core bands plus an env reaction instead of only the p24 plus env reaction (as presently recommended) increased the number of positive interpretations for HTLV-I but had no effect on the number of HTLV-II-positive interpretations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977764      PMCID: PMC268101          DOI: 10.1128/jcm.28.9.2045-2050.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans.

Authors:  H Lee; P Swanson; V S Shorty; J A Zack; J D Rosenblatt; I S Chen
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

Review 2.  Serodiagnosis of infection with the AIDS virus and other human retroviruses.

Authors:  G Schochetman; J S Epstein; T F Zuck
Journal:  Annu Rev Microbiol       Date:  1989       Impact factor: 15.500

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Comparison of immunofluorescence, enzyme immunoassay, and Western blot (immunoblot) methods for detection of antibody to human T-cell leukemia virus type I.

Authors:  D Gallo; M N Hoffman; C K Cossen; J L Diggs; J W Hurst; L M Penning
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

5.  Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region.

Authors:  M Robert-Guroff; S H Weiss; J A Giron; A M Jennings; H M Ginzburg; I B Margolis; W A Blattner; R C Gallo
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

6.  Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors.

Authors:  D W Anderson; J S Epstein; T H Lee; M D Lairmore; C Saxinger; V S Kalyanaraman; D Slamon; W Parks; B J Poiesz; L T Pierik
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

7.  High prevalence of HTLV-II among intravenous drug abusers: PCR confirmation and typing.

Authors:  S Kwok; D Gallo; C Hanson; N McKinney; B Poiesz; J J Sninsky
Journal:  AIDS Res Hum Retroviruses       Date:  1990-04       Impact factor: 2.205

8.  Monoclonal antibodies to human cytomegalovirus: three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants.

Authors:  L Pereira; M Hoffman; D Gallo; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors.

Authors:  A E Williams; C T Fang; D J Slamon; B J Poiesz; S G Sandler; W F Darr; G Shulman; E I McGowan; D K Douglas; R J Bowman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

  9 in total
  7 in total

1.  Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II.

Authors:  C Cossen; S Hagens; R Fukuchi; B Forghani; D Gallo; M Ascher
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Development of a supersensitive polymerase chain reaction method for human T lymphotropic virus type II (HTLV-II) and detection of HTLV-II proviral DNA from blood donors in Japan.

Authors:  T Hamakado; T Matsumoto; Y Koyanagi; K Hayashi; K Fukada; T Kouchiyama; T Yoshida; N Yamamoto
Journal:  Virus Genes       Date:  1992-04       Impact factor: 2.332

3.  Detection and differentiation of antibodies to human T-cell lymphotropic virus types I and II by the immunofluorescence method.

Authors:  D Gallo; L M Penning; C V Hanson
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Sensitivities of radioimmunoprecipitation assay and PCR for detection of human T-lymphotropic type II infection.

Authors:  D Gallo; L M Penning; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

5.  Comparison of four enzyme immunoassays for detection of human T-cell lymphotropic virus type 2 antibodies.

Authors:  D Gallo; E T Yeh; E S Moore; C V Hanson
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

6.  Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.

Authors:  P Horal; W W Hall; B Svennerholm; J Lycke; S Jeansson; L Rymo; M H Kaplan; A Vahlne
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

7.  Evaluation of two commercial human T-cell lymphotropic virus western blot (immunoblot) kits with problem specimens.

Authors:  D Gallo; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.